ModeX Therapeutics, an OPKO Health subsidiary, is a clinical-stage biopharmaceutical company developing next-generation multispecific antibodies as novel therapies for cancer and infectious diseases, as well as nanoparticle technologies for the development of next-generation vaccines. ModeX's modular antibody platforms unite the power of multiple biologic components in a single molecule to create multispecific antibodies with greater versatility and potency to fight complex diseases more effectively than traditional approaches. Our current pipeline includes immuno-oncology candidates against both solid and hematological tumors as well as several of the world's most pressing viral threats. Our founding team includes globally recognized medical innovators with proven track records of delivering breakthroughs for patients. Join our team of groundbreaking scientists and leaders today to change the world tomorrow.
ModeX Therapeutics is seeking a highly-skilled and motivated Scientist I or Scientist II (level dependent upon prior experience and results) to take on a critical role within our Translational Science Team. The position requires working experience in Immunology / Immuno-oncology. Key responsibilities of the role will be to carry out translational studies to support late-development projects, including biomarker discovery. Main activities will consist of in vitro experiments with primary cells, cell lines, and tumor samples, flow cytometry, and multiplex cytokine assays to characterize our candidates. The individual will work in our state-of-the-art laboratory and be responsible for designing and performing experiments, data generation, analysis, and presentation to internal audiences. This is an exciting opportunity to be part of a cross-functional team and contribute to the development of next-generation synthetic biology therapeutics in a fast-paced, rapidly growing biotech company with a bold vision.
Key Responsibilities:
Qualifications:
ModeX Therapeutics is an Equal Opportunity Employer
Software Powered by iCIMS
www.icims.com